MDCO The Medicines Company

24.34
+0.44  (+2%)
Previous Close 23.9
Open 24.1
Price To Book -67.61
Market Cap 1797805364
Shares 73,862,176
Volume 342,235
Short Ratio
Av. Daily Volume 1,432,237

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data 3Q 2019.
Inclisiran - ORION-9
Hypercholesterolemia
Development discontinued due to poor effiacy - November 7, 2016.
MDCO-216 - MILANO-PILOT
Acute coronary syndrome (ACS)
Approved August 29, 2017.
Meropenem-vaborbactam
Complicated urinary tract infections (cUTI)
CRL April 30 2014. Approved June 22 2015
Cangrelor
Reduction of thrombotic cardiovascular events including stent thrombosis in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI)
Approved April 30, 2015.
IONSYS
Acute postoperative pain
Approved August 6 2014 under priority review.
Oritavancin
ABSSSI
Phase 3 trial to be initiated 1H 2018.
Inclisiran
Homozygous familial hypercholesterolemia (HoFH)
Phase 3 enrollment target met - noted March 9, 2018. Data due 3Q 2019.
Inclisiran - ORION-10
Cardiovascular disease (ASCVD)
Phase 3 target enrollment met - noted January 25, 2018. Data due 3Q 2019.
Inclisiran - ORION 11
Cardiovascular disease (ASCVD)